{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T22:50:36Z","timestamp":1774565436772,"version":"3.50.1"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Anaemia is a common sign in multiple myeloma due to multifactorial mechanisms. Apart from the well known factors related to the disease, more recently, the use of several new drugs as the immunotherapeutic ones indicates the emerging role of drug-related mechanisms in the pathophysiology of anaemia in multiple myeloma patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Anaemia associated with immunomodulatory drugs may result from both direct effect on hematopoietic progenitor cells and indirect one mediated by cytokine modulation within the bone marrow microenvironment. The CD38 expression by erythroid lineage cells, suggests that anti-CD38 antibodies may induce apoptosis or functional inhibition of these progenitors, leading to reductions in erythropoiesis. Recent clinical trials also reported ad high incidence of anaemia in multiple myeloma patients treated either with bispecific antibodies or CAR-T cells.<\/jats:p>\n                    <jats:p>Treatment of anaemia in multiple myeloma patients included the use of red blood cell transfusion and erythropoietin-stimulating agents but recently novel agents were under investigation as the activin receptor fusion proteins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The use of the new immunotherapeutic drugs in multiple myeloma patients is associated with an increased incidence of anaemia that should be considered by clinicians particularly in the management of those patients in which coexist other anaemia-related factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/moh.0000000000000911","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T05:00:52Z","timestamp":1770872452000},"page":"65-72","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Advances in the pathophysiology and treatment of anaemia in multiple myeloma"],"prefix":"10.1097","volume":"33","author":[{"given":"Nicola","family":"Giuliani","sequence":"first","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Multiple Myeloma Research Unit, Hematological Hospital Parma"},{"name":"Hematology Unit Hematological Hospital Parma, Parma"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"dalla Palma","sequence":"additional","affiliation":[{"name":"Hematology Unit Hematological Hospital Parma, Parma"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Notarfranchi","sequence":"additional","affiliation":[{"name":"UOC Ematologia Aziendale, Azienda USL Toscana Nordovest, Ospedale Nuovo Apuane, Massa Carrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"R1-20260326","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ajem.2024.11.073","article-title":"An emergency medicine review: multiple myeloma and its complications","volume":"88","author":"Long","year":"2025","journal-title":"Am J Emerg Med"},{"key":"R2-20260326","first-page":"233","article-title":"Anemia in multiple myeloma","volume":"2","author":"Ludwig","year":"2004","journal-title":"Clin Adv Hematol Oncol"},{"key":"R3-20260326","doi-asserted-by":"crossref","first-page":"20508","DOI":"10.1038\/s41598-020-77450-y","article-title":"Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment","volume":"10","author":"Liu","year":"2020","journal-title":"Sci Rep"},{"key":"R4-20260326","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.hoc.2007.08.006","article-title":"Complications of multiple myeloma","volume":"21","author":"Blade","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"R5-20260326","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bjh.19914","article-title":"CD71(+) erythroid cells promote multiple myeloma progression and impair antibacterial immune response","volume":"206","author":"Czubak","year":"2025","journal-title":"Br J Haematol"},{"key":"R6-20260326","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"R7-20260326","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"R8-20260326","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3892\/mco.2023.2705","article-title":"Lenalidomide use in multiple myeloma (Review)","volume":"20","author":"Zhang","year":"2024","journal-title":"Mol Clin Oncol"},{"key":"R9-20260326","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1182\/blood-2014-04-568451","article-title":"Impact of interferon-gamma on hematopoiesis","volume":"124","author":"de Bruin","year":"2014","journal-title":"Blood"},{"key":"R10-20260326","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3324\/haematol.2015.133629","article-title":"Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma","volume":"101","author":"Meletios","year":"2016","journal-title":"Haematologica"},{"key":"R11-20260326","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-0609.2008.01176.x","article-title":"A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma","volume":"82","author":"Dasanu","year":"2009","journal-title":"Eur J Haematol"},{"key":"R12-20260326","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"R13-20260326","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.16213","article-title":"Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure","volume":"188","author":"Siegel","year":"2020","journal-title":"Brit J Haematol"},{"key":"R14-20260326","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma","volume":"128","author":"Dimopoulos","year":"2016","journal-title":"Blood"},{"key":"R15-20260326","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41375-023-01809-z","article-title":"Alternate-day dosing of pomalidomide in relapsed\/refractory multiple myeloma: a multicenter, single-arm phase 2 trial","volume":"37","author":"Zander","year":"2023","journal-title":"Leukemia"},{"key":"R16-20260326","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1182\/blood-2019-124298","article-title":"Translational and clinical evidence of a differentiated profile for the novel CELMoD, Iberdomide (CC-220)","volume":"134","author":"Lonial","year":"2019","journal-title":"Blood"},{"key":"R17-20260326","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.18632\/oncotarget.27973","article-title":"Developing next generation immunomodulatory drugs and their combinations in multiple myeloma","volume":"12","author":"Thakurta","year":"2021","journal-title":"Oncotarget"},{"key":"R18-20260326","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.HS9.0000829600.37424.88","article-title":"P07: results from the CC-220-MM-001 Dose-expansion phase of iberdomide plus dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"6","author":"van de Donk","year":"2022","journal-title":"HemaSphere"},{"key":"R19-20260326","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood-2025-101","article-title":"Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: an update from the phase 2 EMN26 trial","volume":"146","author":"van de Donk","year":"2025","journal-title":"Blood"},{"key":"R20-20260326","doi-asserted-by":"crossref","first-page":"101584","DOI":"10.1016\/j.xcrm.2024.101584","article-title":"Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Van Oekelen","year":"2024","journal-title":"Cell Rep Med"},{"key":"R21-20260326","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.3390\/cancers17203349","article-title":"Daratumumab in transplant-ineligible newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials","volume":"17","author":"Wang","year":"2025","journal-title":"Cancers"},{"key":"R22-20260326","first-page":"e70171","article-title":"Efficacy and safety of quadruplet therapy in newly diagnosed transplant-eligible multiple myeloma: a systematic review and meta-analysis","volume":"8","author":"Channar","year":"2025","journal-title":"Cancer Rep (Hoboken)"},{"key":"R23-20260326","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14740\/jh1085","article-title":"Adverse hematological and non-hematological events in patients with relapsed\/refractory multiple myeloma that are responsive to daratumumab, pomalidomide and dexamethasone","volume":"12","author":"Alkharabsheh","year":"2023","journal-title":"J Hematol"},{"key":"R24-20260326","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3390\/cancers16101854","article-title":"Daratumumab during myeloma induction therapy is associated with impaired stem cell mobilization and prolonged post-transplant hematologic recovery","volume":"16","author":"Mehl","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R25-20260326","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.3390\/cancers16193307","article-title":"First-line use of daratumumab in patients with multiple myeloma shows delayed neutrophil and platelet engraftment after autologous stem cell transplantation: results from a real-life single-center study","volume":"16","author":"Martino","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R26-20260326","doi-asserted-by":"crossref","first-page":"e2024073","DOI":"10.4084\/MJHID.2024.073","article-title":"Effects of daratumumab on hematopoietic stem cells in patients with multiple myeloma who are planned to receive autologous transplantation: what's the relevance?","volume":"16","author":"Sgherza","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R27-20260326","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"R28-20260326","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1182\/blood-2023-184607","article-title":"High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients","volume":"142","author":"Hwa","year":"2023","journal-title":"Blood"},{"key":"R29-20260326","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"R30-20260326","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"key":"R31-20260326","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clml.2017.09.002","article-title":"Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma","volume":"18","author":"Chari","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R32-20260326","doi-asserted-by":"crossref","first-page":"832","DOI":"10.4103\/crst.crst_283_20","article-title":"Daratumumab and its efficacy in refractory myeloma with anemia","volume":"3","author":"Bondili","year":"2020","journal-title":"Cancer Res Stat Treat"},{"key":"R33-20260326","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1182\/blood-2024-194379","article-title":"The safety of repurposing daratumumab for relapsed or refractory autoimmune-antibody-mediated hemolytic anemia","volume":"144","author":"Johnson","year":"2024","journal-title":"Blood"},{"key":"R34-20260326","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"R35-20260326","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"R36-20260326","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41408-025-01334-5","article-title":"Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma","volume":"15","author":"Golmohammadi","year":"2025","journal-title":"Blood Cancer J"},{"key":"R37-20260326","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"R38-20260326","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"R39-20260326","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"R40-20260326","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s40164-024-00573-9","article-title":"New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies","volume":"13","author":"Yang","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"R41-20260326","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R42-20260326","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"key":"R43-20260326","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"R44-20260326","doi-asserted-by":"crossref","first-page":"405016","DOI":"10.1155\/2009\/405016","article-title":"Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis","volume":"2009","author":"Morceau","year":"2009","journal-title":"Mediators Inflamm"},{"key":"R45-20260326","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"key":"R46-20260326","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13046-018-0797-0","article-title":"Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side","volume":"37","author":"Prieto-Bermejo","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"R47-20260326","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","article-title":"Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy","volume":"5","author":"Miller","year":"2021","journal-title":"Blood Adv"},{"key":"R48-20260326","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11899-020-00570-9","article-title":"Supportive care in multiple myeloma","volume":"15","author":"Guzdar","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"R49-20260326","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.clml.2021.07.013","article-title":"Special considerations for supportive care and management of complications in elderly patients with multiple myeloma","volume":"21","author":"George","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R50-20260326","first-page":"CD002042","article-title":"Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion","volume":"10","author":"Carson","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R51-20260326","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.3390\/cancers13194978","article-title":"Management of adverse events and supportive therapy in relapsed\/refractory multiple myeloma","volume":"13","author":"Pozzi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R52-20260326","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2147\/CLEP.S172306","article-title":"Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma","volume":"10","author":"Horvath-Puho","year":"2018","journal-title":"Clin Epidemiol"},{"key":"R53-20260326","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/cncr.26302","article-title":"Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis","volume":"118","author":"Anaissie","year":"2012","journal-title":"Cancer"},{"key":"R54-20260326","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/bloodadvances.2018030387","article-title":"Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update","volume":"3","author":"Bohlius","year":"2019","journal-title":"Blood Adv"},{"key":"R55-20260326","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2013.293","article-title":"International Myeloma Working Group recommendations for global myeloma care","volume":"28","author":"Ludwig","year":"2014","journal-title":"Leukemia"},{"key":"R56-20260326","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00277-017-2950-9","article-title":"Biosimilar epoetin alfa increases haemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot study","volume":"96","author":"Castelli","year":"2017","journal-title":"Ann Hematol"},{"key":"R57-20260326","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11899-024-00740-z","article-title":"Management of toxicities associated with BCMA, GPRC5D, and FcRH5-targeting bispecific antibodies in multiple myeloma","volume":"19","author":"Pan","year":"2024","journal-title":"Curr Hematol Malig Rep"},{"key":"R58-20260326","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"R59-20260326","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41375-019-0420-1","article-title":"The role of TGFbeta in hematopoiesis and myeloid disorders","volume":"33","author":"Bataller","year":"2019","journal-title":"Leukemia"},{"key":"R60-20260326","doi-asserted-by":"crossref","first-page":"115239","DOI":"10.1016\/j.biopha.2023.115239","article-title":"From bench to bedside: the promise of sotatercept in hematologic disorders","volume":"165","author":"Lan","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"R61-20260326","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1172\/JCI133678","article-title":"Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes","volume":"130","author":"Verma","year":"2020","journal-title":"J Clin Invest"},{"key":"R62-20260326","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/bjh.12838","article-title":"An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin","volume":"165","author":"Carrancio","year":"2014","journal-title":"Br J Haematol"},{"key":"R63-20260326","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ajh.23856","article-title":"RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice","volume":"90","author":"Langdon","year":"2015","journal-title":"Am J Hematol"},{"key":"R64-20260326","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.12835","article-title":"Sotatercept in patients with osteolytic lesions of multiple myeloma","volume":"165","author":"Abdulkadyrov","year":"2014","journal-title":"Br J Haematol"}],"container-title":["Current Opinion in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOH.0000000000000911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T22:00:16Z","timestamp":1774562416000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOH.0000000000000911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/moh.0000000000000911","relation":{},"ISSN":["1065-6251","1531-7048"],"issn-type":[{"value":"1065-6251","type":"print"},{"value":"1531-7048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]}}}